Randomized trial compares benefit-risk profiles of dupilumab and upadacitinib in adults with atopic dermatitis, indicating dupilumab's superior profile.
Key Points
This research aims to evaluate and compare the benefit-risk profiles of dupilumab and upadacitinib for treating atopic dermatitis.
Conducted a structured benefit-risk assessment using multicriteria decision analysis based on data from the Heads Up trial.
Measured benefit-risk scores on a scale of 0-100, focusing on patient-relevant outcomes from an independent preference study.
Analyzed efficacy and safety data at 24 weeks and conducted sensitivity analyses with varying weights.
Dupilumab achieved a benefit-risk score of 66 compared to 61 for upadacitinib at week 24.
Sensitivity analysis showed dupilumab consistently had a higher score, while both treatments scored 65 at week 16.
Overall, the assessment highlighted a more favorable benefit-risk balance for dupilumab than for upadacitinib.